FiercePharma1 天
With recent launches and more to come, Amgen's biosimilar business is trending up
After recent launches of biosimilar versions of Eylea and Stelara, Amgen projects its biosimilar sales will reach $4 billion ...
Medscape4 天
FDA Approves Third Tocilizumab Biosimilar
The biosimilar will be available in both subcutaneous and intravenous formulations and has nearly all the same indications as ...
Medscape7 天
Unsustainable Biosimilar Market Leaves Practices, Patients at a Loss
The price to buy certain infused biosimilars can be three times higher than reimbursement, and the problem is growing.
infectiousdiseaseadvisor.com1 天
FDA Approves Tocilizumab Biosimilar Avtozma
The FDA has approved Avtozma® (tocilizumab-anoh), a biosimilar to Actemra®, in both intravenous and subcutaneous formulations.
Managed Healthcare Executive3 天
FDA Approves Third Biosimilar of Actemra
The new biosimilar, Celltrion’s Avtozma, was approved in both IV and subcutaneous forms to treat inflammatory conditions such as arthritis.
The American Journal of Managed Care6 天
FDA Approves Celltrion’s Tocilizumab-anoh, Biosimilar to Actemra
Avtozma, the third biosimilar to Actemra, has received FDA approval for multiple inflammatory diseases and COVID-19, ...
Dr. Reddy’s, Shanghai Henlius Biotech ink $131.6 million cancer drug deal
Dr. Reddy’s to develop and commercialize biosimilar candidate for Johnson & Johnson’s Darzalex drugs with Shanghai Henlius Biotech.